Zenas Biopharma, INC 10-Q quarterly reports

Zenas BioPharma reported increased operating expenses and net losses in its Q2 2026 10-Q filing, alongside progress in its late-stage clinical trials for immunology and inflammation therapies.

Zenas BioPharma, Inc. files a Form 10-Q detailing its first quarter 2026 financial results, including an amendment to its Revenue Participation Right Purchase and Sale Agreement and significant financing activities.

Zenas BioPharma reports increased Q3 2025 net losses and significant cash burn, while advancing its immunology pipeline and securing new financing.

Zenas BioPharma reported increased net losses in Q2 2025 as it significantly ramped up research and development spending for its lead immunology programs, while securing new licensing revenue.

Zenas BioPharma reports a net loss of $33.6 million for Q1 2025, but recognizes $10 million in license and collaboration revenue.

Zenas BioPharma reports a net loss of $38.6 million for the third quarter of 2024, driven by increased research and development expenses, following its recent IPO.